Stempeutics secures US patent

The Bangalore-based firm received the patent from the regulatory body for its stem cell product


The drug is for the treatment of Critical Limb Ischemia

Stempeutics Research's stem-cell based drug Stempeucel has received a process patent from the United States Patent and Trademarks Office.

"The patent granted is a strong recognition for Stempeutics for its sustained excellence of scientific and clinical work," said Mr B N Manohar, chief executive of Stempeutics, in a statement.

The drug is for the treatment of Critical Limb Ischemia (CLI). It directly addresses the root cause of the disease, unlike other drugs which typically treat the symptoms and not the disease itself.

"We believe that the Stempeucel is a game-changer offering, an advanced therapeutic treatment for millions of patient suffering with this dreadful disease," said Mr Manohar.

Stempeutics has already submitted its applications to Drug Controller General of India (DCGI) to obtain marketing authorization approval for Stempeucel.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email